Literature DB >> 8456761

Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation.

P J Olson1, A Woelfel, R J Simpson, J R Foster.   

Abstract

One hundred twenty-two patients treated chronically with amiodarone for sustained ventricular tachycardia or ventricular fibrillation after failing conventional antiarrhythmic therapy were analyzed to determine which factors were predictive of sudden cardiac death during follow-up. The mean left ventricular ejection fraction in the study group was 0.32, and 87% of the patients had coronary artery disease with a prior myocardial infarction. During a median follow-up of 19.5 months, 30 patients died suddenly. The only variable that was predictive of sudden death was left ventricular ejection fraction. Twenty-nine of the 84 patients with ejection fractions < 0.40 died suddenly, compared with 1 of 35 patients with ejection fractions > or = 0.40. The actuarial probability of sudden death at 5 years was 49% when the ejection fraction was < 0.40, and 5% when the ejection fraction was > or = 0.40 (p = 0.0004). These results indicate that patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation whose ejection fractions are > or = 0.40 are at low risk for sudden death. Patients with ejection fractions < 0.40 remain at high risk for sudden death, and should be considered for additional or alternative therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456761     DOI: 10.1016/0002-9149(93)90831-v

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  [ICD therapy as secondary prevention].

Authors:  K Seidl; M Strauss; T Kleemann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

Review 2.  Amiodarone: maximising survival benefit with empiric or guided therapy.

Authors:  G Steinbeck; U Dorwarth; E Hoffmann
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

3.  [Guidelines for the implantation of defibrillators].

Authors:  W Jung; D Andresen; M Block; D Böcker; S H Hohnloser; K-H Kuck; J Sperzel
Journal:  Clin Res Cardiol       Date:  2006-12       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.